[1. Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology 2013 Nov; 41(3–4): 146–155.]Search in Google Scholar
[2. Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs and Aging 2008; 25(7): 541–549.]Search in Google Scholar
[3. Gajewski JB, Drake MJ. Neurological lower urinary tract dysfunction essential terminology. Neurourol Urodyn 2018 Aug 1; 37(S6): S25–31.]Search in Google Scholar
[4. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: Review of the literature and proposal of management guidelines. Mult Scler 2007; 13(7): 915–928.]Search in Google Scholar
[5. Popescu BFG, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: Where do we stand? Contin Lifelong Learn Neurol 2013 Aug; 19(4): 901–921.]Search in Google Scholar
[6. Eyigor S, Karapolat H, Akkoc Y, Yesil H, Ekmekci O. Quality of life in patients with multiple sclerosis and urinary disorders: Reliability and validity of Turkish-language version of Incontinence Quality of Life Scale. J Rehabil Res Dev 2010; 47(1): 67–71.]Search in Google Scholar
[7. Corcos J. A urological challenge: Voiding dysfunction in multiple sclerosis. J Can Urol Assoc 2013; 7(9–10 SUPPL4).]Search in Google Scholar
[8. Tudor KI, Pašiü MB, Škegro SN, Bakula M, Nemir J, Mustaķ F et al. Lower urinary tract symptoms and depression in patients with multiple sclerosis. Psychiatr Danub 2021; 32(2): 113–121.]Search in Google Scholar
[9. Amaro JL, Gameiro MO, Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. Int Urogynecol J 2005; 16(5): 355–358.]Search in Google Scholar
[10. Lúcio A, D’Ancona CAL, Perissinotto MC, McLean L, Damasceno BP, De Moraes Lopes MHB. Pelvic floor muscle training with and without electrical stimulation in the treatment of lower urinary tract symptoms in women with multiple sclerosis. J Wound, Ostomy Cont Nurs 2016 Aug 1; 43(4): 414–419.]Search in Google Scholar
[11. Drake MJ, Apostolidis A, Cocci A, Emmanuel A, Gajewski JB, Harrison SCW et al. Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013. Neurourol Urodyn 2016 Aug 1; 35(6): 657–665.]Search in Google Scholar
[12. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015 Jun 1; 67(6): 1099–1109.]Search in Google Scholar
[13. Yamaguchi O. Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action. Int J Urol 2013 Jan; 20(1): 28–39.]Search in Google Scholar
[14. Amarenco G, Sutory M, Zachoval R, Agarwal M, Del Popolo G, Tretter R et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active – and placebo-controlled SONIC urodynamic study. Neurourol Urodyn 2017 Feb 1; 36(2): 414–421.]Search in Google Scholar
[15. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: A systematic review and meta-analysis. Eur Urol 2012 Nov; 62(5): 816–830.]Search in Google Scholar
[16. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013 Aug; 82(2): 313–320.]Search in Google Scholar
[17. Bosma R, Wynia K, Havlíková E, De Keyser J, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: A meta-analysis. Acta Neurol Scand 2005 Jul; 112(1): 1–5.]Search in Google Scholar
[18. Francomano D, Ilacqua A, Cortese A, Tartaglia G, Lenzi A, Inghilleri M et al. Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study. J Endocrinol Invest 2017 Mar 1; 40(3): 275–279.]Search in Google Scholar
[19. Abo Youssef N, Schneider MP, Mordasini L, Ineichen BV, Bachmann LM, Chartier-Kastler E et al. Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. BJU Int 2017 Apr 1; 119(4): 515–521.]Search in Google Scholar
[20. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol 2011 Oct; 60(4): 742–750.]Search in Google Scholar
[21. Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2013 Nov; 32(8): 1109–1115.]Search in Google Scholar
[22. Tornic J, Panicker JN. The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Curr Neurol Neurosci Rep 2017 Aug 1; 18(8).]Search in Google Scholar
[23. Na HR, Cho ST. Relationship between Lower Urinary Tract Dysfunction and Dementia. Dement Neurocognitive Disord 2020; 19(3): 77.]Search in Google Scholar
[24. Lee HY, Li CC, Juan YS, Chang YH, Yeh HC, Tsai CC et al. Urinary Incontinence in Alzheimer’s Disease: A Population-Based Cohort Study in Taiwan. Am J Alzheimers Dis Other Demen 2017 Feb 1; 32(1): 51–55.]Search in Google Scholar
[25. Orme S, Morris V, Gibson W, Wagg A. Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations. Drugs and Aging 2015 Jul 29; 32(7): 559–567.]Search in Google Scholar
[26. Na HR, Park MH, Cho ST, Lee BC, Park S, Kim KH et al. Urinary incontinence in Alzheimer’s disease is associated with Clinical Dementia Rating-Sum of Boxes and Barthel Activities of Daily Living. Asia-Pacific Psychiatry 2015 Mar 1; 7(1): 113–120.]Search in Google Scholar
[27. Grant RL, Drennan VM, Rait G, Petersen I, Iliffe S. First Diagnosis and Management of Incontinence in Older People with and without Dementia in Primary Care: A Cohort Study Using The Health Improvement Network Primary Care Database. PLoS Med 2013 Aug; 10(8).]Search in Google Scholar
[28. Madan A, Ray S, Burdick D, Agarwal P. Management of lower urinary tract symptoms in Parkinson’s disease in the neurology clinic. Int J Neurosci 2017 Dec 2; 127(12): 1136–1149.]Search in Google Scholar
[29. Averbeck MA, Altaweel W, Manu-Marin A, Madersbacher H. Management of LUTS in patients with dementia and associated disorders. Neurourol Urodyn 2017 Feb 1; 36(2): 245–252.]Search in Google Scholar
[30. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R et al. Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study. JAMA Intern Med 2015 Mar 1; 175(3): 401–407.]Search in Google Scholar
[31. Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA – J Am Med Assoc 2020 Feb 11; 323(6): 548–560.]Search in Google Scholar
[32. Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study. Ther Adv Neurol Disord 2019 May 1; 12.]Search in Google Scholar
[33. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79(4): 368–376.]Search in Google Scholar
[34. Heilman PL, Wang EW, Lewis MM, Krzyzanowski S, Capan CD, Burmeister AR, et al. Tryptophan Metabolites Are Associated with Symptoms and Nigral Pathology in Parkinson’s Disease. Mov Disord 2020 Nov 1; 35(11): 2028–2037.]Search in Google Scholar
[35. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem 2016 Oct 1; 139 Suppl: 318–324.]Search in Google Scholar
[36. Ackley BJ. Nursing Diagnosis Handbook an Evidence Based Guide to Planning Care, Edisi 10. Mosby; 2014.]Search in Google Scholar
[37. Buchman NM, Leurgans SE, Shah RJ, VanderHorst V, Wilson RS, Bachner YG et al. Urinary Incontinence, Incident Parkinsonism, and Parkinson’s Disease Pathology in Older Adults. J Gerontol A Biol Sci Med Sci 2017 Sep 1; 72(9): 1295–1301.]Search in Google Scholar
[38. Thomas LH, Coupe J, Cross LD, Tan AL, Watkins CL. Interventions for treating urinary incontinence after stroke in adults. Cochrane Database Syst Rev 2019 Feb 1; 2.]Search in Google Scholar
[39. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord 2003 May 1; 18(5): 573–578.]Search in Google Scholar
[40. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci Basic Clin 2001 Sep 17; 92(1–2): 76–85.]Search in Google Scholar
[41. Gray R, Stern G, Malone-lee J. Lower urinary tract dysfunction in parkinson’s disease: Changes relate to age and not disease. Age Ageing 1995 Nov; 24(6): 499–504.]Search in Google Scholar
[42. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Urinary function in elderly people with and without leukoaraiosis: Relation to cognitive and gait function. J Neurol Neurosurg Psychiatry 1999; 67(5): 658–660.]Search in Google Scholar
[43. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003 Jan 1; 61(1): 37–49.]Search in Google Scholar
[44. Campos-Sousa RN, Quagliato E, Da Silva BB, De Carvalho RM, Ribeiro CS, De Carvalho DFM. Urinary symptoms in Parkinson’s disease: Prevalence and associated factors. Arq Neuropsiquiatr 2003; 61(2 B): 359–363.]Search in Google Scholar
[45. Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997; 62(5): 507–511.]Search in Google Scholar
[46. Griffiths D. Basics of pressure-flow studies. World J Urol 1995 Feb; 13(1): 30–33.]Search in Google Scholar
[47. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001 Nov; 71(5): 600–666.]Search in Google Scholar
[48. Kuno S, Mizuta E, Yamasaki S, Araki I. Effects of pergolide on nocturia in Parkinson’s disease: Three female cases selected from over 400 patients. Park Relat Disord 2004; 10(3): 181–187.]Search in Google Scholar
[49. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23(7): 689–696.]Search in Google Scholar
[50. Wein AJ, Rackley RR. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol 2006; 175(3 SUPPL.).]Search in Google Scholar
[51. Ishizuka O, Igawa Y, Nishizawa O, Andersson KE. Role of supraspinal tachykinins for volume-and L-dopa-induced bladder activity in normal conscious rats. Neurourol Urodyn 2000; 19(1): 101–109.]Search in Google Scholar
[52. Vaughan CP, Burgio KL, Goode PS, Juncos JL, McGwin G, Muirhead L et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: A randomized clinical trial. Neurourol Urodyn 2019 Aug 1; 38(6): 1737–1744.]Search in Google Scholar
[53. Witte LP, Odekerken VJJ, Boel JA, Schuurman PR, Gerbrandy-Schreuders LC, de Bie RMA. Does deep brain stimulation improve lower urinary tract symptoms in Parkinson’s disease? Neurourol Urodyn 2018 Jan 1; 37(1): 354–359.]Search in Google Scholar
[54. Wang P, Shi J, Zhao L, Li M, Jiao J, Li LY et al. The efficacy and safety of electroacupuncture against urinary incontinence after stroke: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020 Sep 18; 99(38): e22275.]Search in Google Scholar
[55. Kolominsky-Rabas PL, Hilz MJ, Neundoerfer B, Heuschmann PU. Impact of urinary incontinence after stroke: Results from a prospective population-based stroke register. Neurourol Urodyn 2003; 22(4): 322–327.]Search in Google Scholar
[56. Mehdi Z, Birns J, Bhalla A. Post-stroke urinary incontinence. Int J Clin Pract 2013 Nov; 67(11): 1128–1137.]Search in Google Scholar
[57. Tuong NE, Klausner AP, Hampton LJ. A review of post-stroke urinary incontinence. Can J Urol 2016; 23(3): 8265–8270.]Search in Google Scholar
[58. Jacob L, Kostev K. Urinary and fecal incontinence in stroke survivors followed in general practice: A retrospective cohort study. Ann Phys Rehabil Med 2020 Nov 1; 63(6): 488–494.]Search in Google Scholar
[59. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: Does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. Top Stroke Rehabil 2005 Jun; 12(3): 66–76.]Search in Google Scholar
[60. Akkoç Y, Yildiz N, Bardak AN, Ersöz M, Tunç H, Köklü K et al. The course of post-stroke bladder problems and their relation with functional and mental status and quality of life: A six-month, prospective, multicenter study. Turkish J Phys Med Rehabil 2019; 65(4): 335–342.]Search in Google Scholar
[61. Brola W, Fudala M, Flaga S, Ryglewicz D, Potemkowski A. Polski rejestr chorych na stwardnienie rozsiane – Stan obecny, perspektywy i problemy. Aktual Neurol 2015; 15(2): 68–73.]Search in Google Scholar
[62. Katan M, Luft A. Global Burden of Stroke. Semin Neurol 2018 Apr 1; 38(2): 208–211.]Search in Google Scholar
[63. Starzenie się ludności Polski na tle Europy w perspektywie 2030 i 2050 r. w świetle wybranych parametrów [Internet]. Available from: https://repozytorium.ka.edu.pl/handle/11315/381 [cited 31 Oct 2021].]Search in Google Scholar
[64. Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson KE et al. Can incontinence be cured? A systematic review of cure rates. BMC Med 2017 Mar 24; 15(1).]Search in Google Scholar
[65. Melo LS de, Ercole FF, Oliveira DU de, Pinto TS, Victoriano MA, Alcoforado CLGC. Urinary tract infection: a cohort of older people with urinary incontinence. Rev Bras Enferm 2017 Jul 1; 70(4): 838–844.]Search in Google Scholar
[66. Caljouw MA, den Elzen WPJ, Cools HJ, Gussekloo J. Predictive factors of urinary tract infections among the oldest old in the general population. A population-based prospective follow-up study. BMC Med 2011 Jun 16; 9: 57.]Search in Google Scholar
[67. Moore EE, Jackson SL, Boyko EJ, Scholes D, Fihn SD. Urinary incontinence and urinary tract infection: Temporal relationships in postmenopausal women. Obstet Gynecol 2008; 111(2): 317–323.]Search in Google Scholar
[68. Aslam N, Mahreen K. Role of Urinary Incontinence in Depression and Life Satisfaction in Geriatric Patients. Pakistan J Public Heal 2019; 8(4): 185–189.]Search in Google Scholar
[69. Siddiqui NY, Wiseman JB, Cella D, Bradley CS, Lai HH, Helmuth ME et al. Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence. J Urol 2018 Oct 1; 200(4): 848–855.]Search in Google Scholar
[70. Valvanne J, Juva K, Erkinjuntti T, Tilvis R. Major depression in the elderly: A population study in Helsinki. Int Psychogeriatrics 1996; 8(3): 437–443.]Search in Google Scholar
[71. Ferreira M, Abbade L, Bocchi SCM, Miot HA, Boas PV, Guimaraes HQCP. Incontinence-associated dermatitis in elderly patients: prevalence and risk factors. Rev Bras Enferm 2020; 73(3): e20180475.]Search in Google Scholar
, 